Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

10.1186/bcr3231

Saved in:

Bibliographic Details
Main Authors:	Byrski, T, Dent, R, Blecharz, P, Foszczynska-Kloda, M, Gronwald, J, Huzarski, T, Cybulski, C, Marczyk, E, Chrzan, R, Eisen, A, Lubinski, J, Narod, S.A
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	aromatase inhibitor BRCA1 protein cisplatin cyclophosphamide dexamethasone docetaxel doxorubicin epidermal growth factor receptor 2 estrogen receptor fluorouracil ondansetron pabi dexamethason progesterone receptor unclassified drug antineoplastic agent adult aged anemia article breast cancer cancer chemotherapy cancer survival clinical article drug withdrawal female gene mutation heterozygote human metastasis multiple cycle treatment nausea neutropenia open study overall survival phase 2 clinical trial treatment outcome Breast Neoplasms clinical trial computer assisted tomography genetics metabolism middle aged mortality multicenter study mutation pathology tumor suppressor gene Adult Aged Antineoplastic Agents Cisplatin Female Genes, BRCA1 Heterozygote Humans Middle Aged Mutation Neoplasm Metastasis Receptors, Estrogen Receptors, Progesterone Tomography, X-Ray Computed Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183230
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183230
record_format	dspace
spelling	sg-nus-scholar.10635-1832302024-11-09T10:39:35Z Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer Byrski, T Dent, R Blecharz, P Foszczynska-Kloda, M Gronwald, J Huzarski, T Cybulski, C Marczyk, E Chrzan, R Eisen, A Lubinski, J Narod, S.A DUKE-NUS MEDICAL SCHOOL aromatase inhibitor BRCA1 protein cisplatin cyclophosphamide dexamethasone docetaxel doxorubicin epidermal growth factor receptor 2 estrogen receptor fluorouracil ondansetron pabi dexamethason progesterone receptor unclassified drug antineoplastic agent cisplatin estrogen receptor progesterone receptor adult aged anemia article breast cancer cancer chemotherapy cancer survival clinical article drug withdrawal female gene mutation heterozygote human metastasis multiple cycle treatment nausea neutropenia open study overall survival phase 2 clinical trial treatment outcome Breast Neoplasms clinical trial computer assisted tomography genetics metabolism metastasis middle aged mortality multicenter study mutation pathology tumor suppressor gene Adult Aged Antineoplastic Agents Breast Neoplasms Cisplatin Female Genes, BRCA1 Heterozygote Humans Middle Aged Mutation Neoplasm Metastasis Receptors, Estrogen Receptors, Progesterone Tomography, X-Ray Computed Treatment Outcome 10.1186/bcr3231 Breast Cancer Research 14 4 R110 2020-11-10T00:35:57Z 2020-11-10T00:35:57Z 2012 Article Byrski, T, Dent, R, Blecharz, P, Foszczynska-Kloda, M, Gronwald, J, Huzarski, T, Cybulski, C, Marczyk, E, Chrzan, R, Eisen, A, Lubinski, J, Narod, S.A (2012). Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Research 14 (4) : R110. ScholarBank@NUS Repository. https://doi.org/10.1186/bcr3231 14655411 https://scholarbank.nus.edu.sg/handle/10635/183230 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	aromatase inhibitor BRCA1 protein cisplatin cyclophosphamide dexamethasone docetaxel doxorubicin epidermal growth factor receptor 2 estrogen receptor fluorouracil ondansetron pabi dexamethason progesterone receptor unclassified drug antineoplastic agent cisplatin estrogen receptor progesterone receptor adult aged anemia article breast cancer cancer chemotherapy cancer survival clinical article drug withdrawal female gene mutation heterozygote human metastasis multiple cycle treatment nausea neutropenia open study overall survival phase 2 clinical trial treatment outcome Breast Neoplasms clinical trial computer assisted tomography genetics metabolism metastasis middle aged mortality multicenter study mutation pathology tumor suppressor gene Adult Aged Antineoplastic Agents Breast Neoplasms Cisplatin Female Genes, BRCA1 Heterozygote Humans Middle Aged Mutation Neoplasm Metastasis Receptors, Estrogen Receptors, Progesterone Tomography, X-Ray Computed Treatment Outcome
spellingShingle	aromatase inhibitor BRCA1 protein cisplatin cyclophosphamide dexamethasone docetaxel doxorubicin epidermal growth factor receptor 2 estrogen receptor fluorouracil ondansetron pabi dexamethason progesterone receptor unclassified drug antineoplastic agent cisplatin estrogen receptor progesterone receptor adult aged anemia article breast cancer cancer chemotherapy cancer survival clinical article drug withdrawal female gene mutation heterozygote human metastasis multiple cycle treatment nausea neutropenia open study overall survival phase 2 clinical trial treatment outcome Breast Neoplasms clinical trial computer assisted tomography genetics metabolism metastasis middle aged mortality multicenter study mutation pathology tumor suppressor gene Adult Aged Antineoplastic Agents Breast Neoplasms Cisplatin Female Genes, BRCA1 Heterozygote Humans Middle Aged Mutation Neoplasm Metastasis Receptors, Estrogen Receptors, Progesterone Tomography, X-Ray Computed Treatment Outcome Byrski, T Dent, R Blecharz, P Foszczynska-Kloda, M Gronwald, J Huzarski, T Cybulski, C Marczyk, E Chrzan, R Eisen, A Lubinski, J Narod, S.A Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
description	10.1186/bcr3231
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Byrski, T Dent, R Blecharz, P Foszczynska-Kloda, M Gronwald, J Huzarski, T Cybulski, C Marczyk, E Chrzan, R Eisen, A Lubinski, J Narod, S.A
format	Article
author	Byrski, T Dent, R Blecharz, P Foszczynska-Kloda, M Gronwald, J Huzarski, T Cybulski, C Marczyk, E Chrzan, R Eisen, A Lubinski, J Narod, S.A
author_sort	Byrski, T
title	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
title_short	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
title_full	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
title_fullStr	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
title_full_unstemmed	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
title_sort	results of a phase ii open-label, non-randomized trial of cisplatin chemotherapy in patients with brca1-positive metastatic breast cancer
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183230
_version_	1821215242888151040

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Similar Items